Bloomberg News
@Bloomberg-News·2.8M subscribers·40.1K videos
Pfizer Studies 3-Dose Covid Shot for Young Kids as Parents Wait
Posted
December 17, 2021
Views
599
Likes
5
Comments
9
Engagement
December 17, 2021
599
5
9
2.34%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
1:01Now PlayingPfizer Inc. and BioNTech SE plan to study a three-dose regimen of their Covid-19 vaccine in young children 6 months to 4 years old, a move that may extend the wait for anxious parents as fast-spreading variants complicate clinical trials.
When tested in children ages 2 to 4, the two-shot regimen failed to meet a laboratory standard for immune response set in an older age group, according to a statement. The vaccine partners said they amended their clinical trial protocol following a request by an external, independent data-monitoring committee. No safety concerns were identified among the young children.
Subscribe to our YouTube channel
Subscribe to our newest channel Quicktake Explained
Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
To watch complete coverage on Bloomberg Quicktake 24/7, visit or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.
Have a story to tell? Fill out this survey for a chance to have it featured on Bloomberg Quicktake
Connect with us on…
Breaking News on YouTube
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
